Thiogenesis Therapeutics Company Description

Thiogenesis Therapeutics, Corp., a biopharmaceutical company, develops thiol-active therapeutic compounds to treat unmet pediatric medical needs.

The company’s lead product candidate comprises TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke, other mitochondrial diseases, Rett syndrome, and pediatric non-alcoholic fatty liver diseases.

Thiogenesis Therapeutics, Corp. is headquartered in Toronto, Canada.

Thiogenesis Therapeutics, Corp.

Country	Canada
Industry	Biotechnology
Sector	Healthcare
CEO	Patrice Rioux

Contact Details

Address: 4 King Street West Toronto, Ontario M5H 1B6 Canada
Phone	888 223 9165
Website	thiogenesis.com

Stock Details

Ticker Symbol	TTI
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	CAD
SIC Code	2836

Key Executives

Name	Position
Dr. Patrice P. Rioux M.D., Ph.D.	Co-Founder, Chief Executive Officer and Director
Brook G. Riggins C.F.A.	Chief Financial Officer, Secretary and Director
Mary Jo Bagger	Consultant for Clinical Operations